We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+37.22%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$296M
AUM Growth
-$29.1M
Cap. Flow
-$1.25M
Cap. Flow %
-0.42%
Top 10 Hldgs %
37.63%
Holding
99
New
29
Increased
28
Reduced
20
Closed
20
Avg Time Held Equity + Options
2.5 quarters
Top 10 Avg Time Held Equity + Options
0.8 quarters
Top 20 Avg Time Held Equity + Options
1.6 quarters
Avg Time Held Equity only
2.8 quarters
Top 10 Avg Time Held Equity only
0.9 quarters
Top 20 Avg Time Held Equity only
2.2 quarters

Top Buys

Rank Stock Value
1
PSTX icon
Poseida Therapeutics, Inc. Common Stock
PSTX
+$7.19M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$6.21M
3
VRAY
ViewRay, Inc.
VRAY
+$5.34M
4
PLRX icon
Pliant Therapeutics
PLRX
+$4.01M
5
NKTX icon
Nkarta
NKTX
+$3.6M

Top Sells

Rank Stock Value
1
ITCI icon
Intra-Cellular Therapies Inc.
ITCI
+$9.29M
2
APLS icon
Apellis Pharmaceuticals
APLS
+$5.87M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$4.91M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$4.34M
5
BIIB icon
Biogen
BIIB
+$4.25M

Sector Composition

Rank Sector Weight
1 Healthcare 79.75%
2 Miscellaneous 20.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BLU
1
DELISTED
BELLUS Health Inc.
BLU
$17.5M 5.91%
1,655,775
+92,818
+6% +$986K
2021 Q2
5 quarters
RLMD icon
2
PUT
Relmada Therapeutics
RLMD
$358M
$14.5M 4.92%
+393,000
New +$10.9M
2022 Q3
0 quarters
RXDX
3
PUT
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$12.1M 4.09%
204,700
-97,000
-32% -$4.44M
2022 Q2
1 quarter
VCYT icon
4
Veracyte
VCYT
$3.47B
$11.1M 3.74%
665,854
-52,935
-7% -$1.19M
2021 Q1
6 quarters
AKRO icon
5
DELISTED
Akero Therapeutics
AKRO
$10.2M 3.46%
300,000
+39,675
+15% +$607K
2022 Q2
1 quarter
AVXL icon
6
PUT
Anavex Life Sciences
AVXL
$137M
$9.73M 3.29%
942,500
+25,400
+3% +$268K
2022 Q2
1 quarter
MORF icon
7
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$9.18M 3.11%
324,421
-94,239
-23% -$2.63M
2020 Q4
7 quarters
COGT icon
8
Cogent Biosciences
COGT
$4.87B
$9.05M 3.06%
606,608
-214,346
-26% -$2.94M
2020 Q4
7 quarters
PSTX icon
9
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$9.02M 3.05%
2,554,277
+2,173,671
+571% +$7.19M
2021 Q4
3 quarters
XENE icon
10
Xenon Pharmaceuticals
XENE
$3.33B
$8.88M 3%
245,992
+13,362
+6% +$480K
2021 Q3
4 quarters
ACRS icon
11
Aclaris Therapeutics
ACRS
$511M
$8.56M 2.9%
543,776
+4,231
+0.8% +$66.7K
2021 Q1
6 quarters
VRAY
12
DELISTED
ViewRay, Inc.
VRAY
$8.46M 2.86%
2,324,066
+1,591,326
+217% +$5.34M
2021 Q2
5 quarters
ISEE
13
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.95M 2.69%
443,100
+12,200
+3% +$160K
2022 Q1
2 quarters
MRSN icon
14
DELISTED
Mersana Therapeutics
MRSN
$6.72M 2.27%
39,763
+5,763
+17% +$937K
2022 Q2
1 quarter
PRTA icon
15
Prothena Corp
PRTA
$429M
$6.67M 2.26%
+110,000
New +$3.48M
2022 Q3
0 quarters
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$29.9B
$6.51M 2.2%
+32,545
New +$6.21M
2022 Q3
0 quarters
VERU icon
17
PUT
Veru
VERU
$37.3M
$6.34M 2.14%
55,000
-23,040
-30% -$3.32M
2022 Q2
1 quarter
ITCI icon
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$6.33M 2.14%
136,126
-177,836
-57% -$9.29M
2020 Q4
7 quarters
APEN
19
DELISTED
Apollo Endosurgery, Inc.
APEN
$6.26M 2.12%
1,136,206
+61,327
+6% +$340K
2021 Q4
3 quarters
MRUS icon
20
DELISTED
Merus
MRUS
$5.91M 2%
295,136
-173,977
-37% -$4.15M
2021 Q1
6 quarters
CERS icon
21
Cerus
CERS
$455M
$5.82M 1.97%
1,616,459
-477,402
-23% -$2.28M
2021 Q2
5 quarters
CTIC
22
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$5.72M 1.94%
983,516
-396,595
-29% -$2.47M
2021 Q4
3 quarters
CLNN icon
23
PUT
Clene
CLNN
$48.2M
$4.86M 1.64%
+86,740
New +$5.75M
2022 Q3
0 quarters
INSM icon
24
Insmed
INSM
$21.1B
$4.83M 1.63%
224,016
+11,534
+5% +$277K
2020 Q4
7 quarters
NKTX icon
25
Nkarta
NKTX
$150M
$4.77M 1.61%
362,377
+251,614
+227% +$3.6M
2022 Q2
1 quarter
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, Silverarc Capital Management held 99 positions worth $296M, down 9% from $325M the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Silverarc Capital Management's Q3 2022 filing shows 29 new, 28 increased, 20 reduced and 20 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 32,545 shares worth $6.51M. The largest sale was Intra-Cellular Therapies Inc., an estimated $9.29M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 66% a quarter earlier, followed by Miscellaneous.

  • Silverarc Capital Management's largest Q3 2022 buy was Alnylam Pharmaceuticals: 32,545 shares worth $6.51M.
  • Silverarc Capital Management added most to Poseida Therapeutics, Inc. Common Stock in Q3 2022, an estimated $7.19M increase.
  • Silverarc Capital Management's biggest Q3 2022 reduction was Intra-Cellular Therapies Inc., cutting an estimated $9.29M.
  • Silverarc Capital Management fully exited Apellis Pharmaceuticals in Q3 2022, selling an estimated $5.87M.
  • Silverarc Capital Management's ten largest holdings make up 38% of its $296M portfolio in Q3 2022.
  • Silverarc Capital Management opened 29 new positions and closed 20 in Q3 2022.
  • Silverarc Capital Management's portfolio value fell 9% quarter-over-quarter to $296M.

Based on Silverarc Capital Management's 13F filing for Q3 2022, filed 28 Oct 2022.